Sunovion Pharmaceuticals said today that the FDA accepted its new drug application for a sublingual film designed to treat motor fluctuations in people living with Parkinson’s disease.
The U.S. regulatory agency is slated to make a decision regarding Sunovion’s application by January 29.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease appeared first on MassDevice.